OTC Markets Group Welcomes Medicenna Therapeutics Corp. to OTCQX
OTC Markets Group has announced that Medicenna Therapeutics Corp. has qualified to trade on the OTCQX Best Market. Previously trading on the OTCQB Venture Market, Medicenna will now trade under the symbol MDNAF. This upgrade signifies Medicenna's adherence to high financial standards, corporate governance best practices, and compliance with securities laws. The move aims to enhance visibility among U.S. investors, improve liquidity, and broaden stock access. CEO Fahar Merchant highlighted the importance of this milestone in strengthening their capital markets strategy.
OTC Markets Group ha annunciato che Medicenna Therapeutics Corp. ha ottenuto l'idoneità per essere quotata sul OTCQX Best Market. In precedenza, Medicenna era quotata sul mercato OTCQB Venture, ora commercerà con il simbolo MDNAF. Questo passaggio segna l'aderenza di Medicenna a elevati standard finanziari, migliori pratiche di governance aziendale e conformità con le leggi sui titoli. L'obiettivo è aumentare la visibilità tra gli investitori statunitensi, migliorare la liquidità e ampliare l'accesso alle azioni. Il CEO Fahar Merchant ha sottolineato l'importanza di questo traguardo nel rafforzare la loro strategia nei mercati dei capitali.
OTC Markets Group ha anunciado que Medicenna Therapeutics Corp. ha calificado para comerciar en el OTCQX Best Market. Anteriormente negociando en el mercado OTCQB Venture, Medicenna ahora comerciará bajo el símbolo MDNAF. Esta mejora significa la adhesión de Medicenna a altos estándares financieros, mejores prácticas de gobernanza corporativa y cumplimiento con las leyes de valores. El movimiento tiene como objetivo aumentar la visibilidad entre los inversores de EE.UU., mejorar la liquidez y ampliar el acceso a las acciones. El CEO Fahar Merchant destacó la importancia de este hito en el fortalecimiento de su estrategia de mercados de capitales.
OTC Markets Group는 Medicenna Therapeutics Corp.가 OTCQX 베스트 마켓에서 거래할 자격을 얻었다고 발표했습니다. 이전에는 OTCQB 벤처 마켓에서 거래되던 Medicenna는 이제 MDNAF라는 기호로 거래됩니다. 이번 업그레이드는 Medicenna의 높은 재무 기준, 기업 거버넌스 모범 사례 및 증권법 준수를 나타냅니다. 이 움직임은 미국 투자자들 사이에서 가시성을 높이고 유동성을 개선하며 주식 접근성을 넓히는 것을 목표로 하고 있습니다. CEO 파하르 머천트는 자본 시장 전략을 강화하는 데 있어 이 이정표의 중요성을 강조했습니다.
OTC Markets Group a annoncé que Medicenna Therapeutics Corp. a été qualifiée pour négocier sur le OTCQX Best Market. Précédemment négociée sur le marché OTCQB Venture, Medicenna négociera désormais sous le symbole MDNAF. Cette mise à niveau signifie l'adhésion de Medicenna à des normes financières élevées, aux meilleures pratiques de gouvernance d'entreprise et au respect des lois sur les valeurs mobilières. Ce mouvement vise à accroître la visibilité parmi les investisseurs américains, à améliorer la liquidité et à élargir l'accès aux actions. Le PDG Fahar Merchant a souligné l'importance de cette étape dans le renforcement de leur stratégie sur les marchés des capitaux.
OTC Markets Group hat bekannt gegeben, dass Medicenna Therapeutics Corp. für den Handel im OTCQX Best Market qualifiziert ist. Zuvor wurde Medicenna am OTCQB Venture Market gehandelt, jetzt wird unter dem Symbol MDNAF gehandelt. Dieses Upgrade bedeutet, dass Medicenna hohen finanziellen Standards, Best Practices der Unternehmensführung und der Einhaltung der Wertpapiergesetze entspricht. Das Ziel ist es, die Sichtbarkeit bei US-Investoren zu erhöhen, die Liquidität zu verbessern und den Zugang zu Aktien zu erweitern. CEO Fahar Merchant betonte die Bedeutung dieses Meilensteins für die Stärkung ihrer Kapitalmarktstrategie.
- Medicenna Therapeutics Corp. upgraded to OTCQX Best Market.
- Trading under the symbol MDNAF on OTCQX.
- Enhanced visibility among U.S. investors.
- Improved liquidity for Medicenna's stock.
- Broadened access to stock for U.S. and international investors.
- None.
NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Medicenna Therapeutics Corp. (TSX: MDNA; OTCQX: MDNAF), a clinical-stage immunotherapy company, has qualified to trade on the OTCQX® Best Market. Medicenna Therapeutics Corp. upgraded to OTCQX from the OTCQB® Venture Market.
Medicenna Therapeutics Corp. begins trading today on OTCQX under the symbol “MDNAF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.
The OTCQX Market is designed for established, investor-focused U.S. and international companies. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws. Graduating to the OTCQX Market marks an important milestone for companies, enabling them to demonstrate their qualifications and build visibility among U.S. investors.
“We are thrilled to be moving up to the OTCQX Best Market,” said Fahar Merchant, Ph.D., President and CEO of Medicenna. “This step strengthens our capital markets strategy by highlighting our dedication to transparency, improving liquidity, and broadening access to our stock for both U.S. and international investors.”
About Medicenna Therapeutics Corp.
Medicenna is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Medicenna’s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Medicenna’s IL-4 Empowered Superkine, bizaxofusp (formerly MDNA55), has been studied in 5 clinical trials enrolling over 130 patients, including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and Orphan Drug status from the FDA and FDA/EMA, respectively. Medicenna’s early-stage high-affinity IL-2β biased IL-2/IL-15 Super-antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft-versus host diseases. Medicenna’s early-stage BiSKITs™ (Bifunctional SuperKine ImmunoTherapies) and the T-MASK™ (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically “cold” tumors.
For more information, please visit www.medicenna.com, and follow us on Twitter and LinkedIn.
About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates regulated markets for trading 12,000 U.S. and international securities. Our data-driven disclosure standards form the foundation of our three public markets: OTCQX® Best Market, OTCQB® Venture Market and Pink® Open Market.
Our OTC Link® Alternative Trading Systems (ATSs) provide critical market infrastructure that broker-dealers rely on to facilitate trading. Our innovative model offers companies more efficient access to the U.S. financial markets.
OTC Link ATS, OTC Link ECN and OTC Link NQB are each an SEC regulated ATS, operated by OTC Link LLC, a FINRA and SEC registered broker-dealer, member SIPC.
To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.
Subscribe to the OTC Markets RSS Feed
Media Contact:
OTC Markets Group Inc., +1 (212) 896-4428, media@otcmarkets.com
FAQ
What is the new trading symbol for Medicenna Therapeutics Corp. on OTCQX?
What market did Medicenna Therapeutics Corp. upgrade from?
What are the benefits of Medicenna Therapeutics Corp. trading on OTCQX?
What are the requirements for a company to qualify for the OTCQX Best Market?
Where can U.S. investors find financial disclosures and real-time quotes for Medicenna Therapeutics Corp.?
